The number of days alive and out of the hospital within the first 90 days of surgery is greater for robot-assisted surgery, but the clinical significance of the findings unclear.
Positive surgical margins in patients undergoing robotic partial nephrectomy for renal tumors are associated with adverse oncologic outcomes, a study revealed.
An interim analysis suggests that axitinib given to patients with complex clear cell renal cell carcinoma tumors significantly reduces tumor size and complexity.
Immune checkpoint inhibitors may be more beneficial than tyrosine kinase inhibitors for patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma.